Innovating Works

filtrando por convocatoria: HORIZON-MISS-2021-CANCER-02-03

MammoScreen: Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate... FONDAZIONE TOSCANA LIFE SCIENCES tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Res...
2022-11-28 - 2026-11-30 | Financiado
PANCAID: PANcreatic CAncer Initial Detection via liquid biopsy UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will theref...
2022-12-02 - 2027-12-31 | Financiado
EUonQoL: Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 EUonQoL aims to develop, pilot and validate the EUonQoL-Kit, a patient-driven, unified system for the assessment of quality of life (QoL) ba...
2023-01-01 - 2026-12-31 | Financiado
DIOPTRA: EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INI... EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTON tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 DIOPTRA aims to introduce a front-line screening tool that will consider risk factors and protein biomarkers for pinpointing individuals at...
2023-01-01 - 2026-12-31 | Financiado
ONCOSCREEN: A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based... EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in scre...
2023-01-01 - 2026-12-31 | Financiado
SANGUINE: Early detection and screening of hematological malignancies TEL AVIV UNIVERSITY tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Project SANGUINE addresses the objectives raised by the Cancer Mission Call, which emerged from the growing societal challenge faced by Euro...
2023-01-01 - 2025-12-31 | Financiado
LUCIA: Understanding Lung Cancer related risk factors and their Impact TECHNION ISRAEL INSTITUTE OF TECHNOLOGY tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Lung Cancer (LC) is the biggest cancer killer worldwide, with five-year survival following diagnosis varying between 5% to 25%. Though tobac...
2023-01-01 - 2026-12-31 | Financiado
ELMUMY: Elucidation of risk factors and health determinants associated with PROGRESSION of Monoclonal Gammop... ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently there is no effective cure since event...
2023-01-01 - 2026-12-31 | Financiado
ThermoBreast: An innovative non-contact and harmless screening modality set to change the course of breast cancer... THERMOMIND LTD tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2....
2023-01-01 - 2026-12-31 | Financiado
GENIAL: Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma UNIVERSITE LIBRE DE BRUXELLES tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related...
2023-01-01 - 2027-12-31 | Financiado
MELCAYA: Novel health care strategies for melanoma in children adolescents and young adults FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 "In childhood, adolescence and young adults (CAYA), melanoma is under-studied and non-existing tailored clinical guidelines and standardized...
2022-12-01 - 2026-11-30 | Financiado